ALMA MANLANGIT: Open Payments
NPI 1316345788 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$348 in 11 payments from 8 companies in 2025. Trend: 2023 $24 · 2024 $0 · 2025 $348
Food & beverage: $348
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $129 |
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Edwards Lifesciences Corporation | 1 | $35 |
| Astellas Pharma US Inc | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: INGREZZA, Kerendia, ZORYVE, FARXIGA, Veozah, Dexcom G6 Transmitter, CAPLYTA, BREZTRI.
Industry payments across NV — which companies pay providers there.
